A.R.R.E.S.T® signal for myopia management

The majority of the lens designs for myopia management apply bifocal or multifocal optics in both contact lens and spectacle lens modes. The use of non-single vision optics inevitably causes unwarranted visual disturbances. Efforts to improve visual performance while retaining a therapeutic benefit have been challenging for scientists and lens manufacturers.

Preliminary evidence from animal studies indicates the manipulation of retinal ganglion cell pathways may produce variable effects on short-term choroidal thickness. The short-term variations in the choroidal thickness provide directional cues for refractive error development and progression.


nthalmic is currently developing novel ophthalmic lens designs based on providing an A.R.R.E.S.T® (Active Rise in Retinal Encoding of Spatio-Temporal) signal.


This cue purposefully modulates the on- and off-centre retinal ganglion cell activity to slow the rate of progressive myopia. Ophthalmic lens designs utilising the A.R.R.E.S.T® signal are one of the first designs that do not leverage optical defocus or scatter to manage progressive myopia.

Advanced optical modelling is currently underway to engineer optics to ensure quasi-single vision performance, which will be followed by prototyping and clinical evaluations. Following the dispensing trial, a long-term clinical trial is planned to determine whether the proposed A.R.R.E.S.T® signal is beneficial in maintaining the non-myopiagenic signal for progressive myopia.


If you are interested in collaboration or partnership to elevate and accelerate our next-generation solutions, please contact us.